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ABSTRACT  24 
 25 
To identify new compounds with anti-human cytomegalovirus (HCMV) 26 
activity and new anti-HCMV targets, we developed a high throughput strategy to 27 
screen a GlaxoSmithKline (GSK) Published Kinase Inhibitor Set (PKIS). This 28 
collection contains a range of extensively characterized compounds grouped into 29 
chemical families (chemotypes). From our screen we identified compounds within 30 
chemotypes that impede HCMV protein production and identified kinase proteins 31 
associated with inhibition of HCMV protein production that are potential novel 32 
anti-HCMV targets. We focused our study on a top ³KLW´ LQ RXU VFUHHQ 6%-33 
734117, which we found inhibits productive replication of several HCMV strains. 34 
Kinase selectivity data indicated that SB-734117 exhibits polypharmacology and 35 
is an inhibitor of several proteins from the AGC and CMCG kinase groups. Using 36 
western blotting we found that SB-734711 inhibited accumulation of HCMV 37 
immediate-early proteins, phosphorylation of cellular proteins involved in 38 
immediate-early protein production (CREB and histone H3) and histone H3 lysine 39 
36 trimethylation (H3K36me3).  Therefore, we identify SB-734117 as a novel 40 
anti-HCMV compound and find that inhibition of AGC and CMCG kinase proteins 41 
during productive HCMV replication is associated with inhibition of viral protein 42 
production and prevents post-translational modification of cellular factors 43 
associated with viral protein production.    44 
 3 
INTRODUCTION 45 
 46 
 Disease associated with human cytomegalovirus (HCMV) infection affects 47 
a range of immunodeficient individuals [1]. As yet, there is no widely available 48 
vaccine against HCMV [2] and disease management largely rests on the use of 49 
anti-HCMV drugs [1, 3]. The most widely used anti-HCMV drugs (including the 50 
frontline drug ganciclovir) target the viral DNA polymerase, thereby inhibiting 51 
HCMV replication [3]. However, there are drawbacks to the use of ganciclovir 52 
and other currently available anti-HCMV drugs, including the development of 53 
drug resistant virus [3]. Furthermore, HCMV not only undergoes productive 54 
replication but can also enter a latent state from which the virus can reactivate. 55 
Currently, there is no effective treatment to clear latent HCMV infection.  56 
 Several novel anti-HCMV drugs are under development [1, 3, 4]. One 57 
strategy to expand the range of anti-HCMV drugs available is to identify existing 58 
compounds with hitherto unappreciated anti-HCMV activity. A large number of 59 
currently available compounds inhibit protein kinases in each of the groups that 60 
comprise the human kinome. Protein kinases are involved in many aspects of 61 
HCMV replication and pathogenesis, including intracellular signaling that results 62 
in transcription from the HCMV major immediate early promoter (MIEP), which 63 
stimulates a transcriptional cascade (immediate-early to early to late gene 64 
transcription) required for productive HCMV replication and reactivation from 65 
latency [1]. Therefore, protein kinase inhibitors could inhibit productive HCMV 66 
replication or reactivation from latency and a number of kinase inhibitors with 67 
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anti-HCMV activity have been identified [3]. Furthermore, it is possible that the 68 
full complement of protein kinases that are required for HCMV replication have 69 
yet to be identified. Therefore, kinase inhibitors could be used as chemical 70 
probes to identify kinase proteins required for HCMV replication, many of which 71 
could be novel anti-HCMV drug targets. However, an important consideration 72 
when using kinase inhibitors is that compounds targeting the conserved ATP-73 
binding site of a kinase protein can display polypharmacology and are capable of 74 
inhibiting several kinase proteins or proteins outside the kinome, such as G-75 
protein coupled receptors (GPCRs) [5-7]. Therefore, knowledge of kinase 76 
selectivity is important when discussing the use of kinase inhibitors as drugs or 77 
chemical probes [5].  78 
 We utilized a high throughput screening methodology to assess the ability 79 
of compounds within a GlaxoSmithKline (GSK) Published Kinase Inhibitor Set 80 
(PKIS) [8] to inhibit HCMV protein production. This compound library contained a 81 
range of extensively characterized compounds organized into structurally related 82 
collections of compound families (chemotypes) [7, 8]. Known characteristics of 83 
compounds within this GSK PKIS collection include kinase selectivity, compound 84 
structures and off-targets effects. Therefore, screening of this compound library 85 
allowed identification of both compounds and chemotypes with anti-HCMV 86 
activity, identification of novel anti-HCMV drug targets and permitted the on and 87 
off-targets effects of compounds identified in the screening process to be 88 
considered. These data lead to investigation of the anti-HCMV activity of a top 89 
³KLW´LQRXUVFUHHQ6%-734117.   90 
 5 
RESULTS 91 
 92 
High throughput screening of a GSK PKIS library to identify protein 93 
kinase inhibitors with anti-HCMV activity. To identify compounds with anti-94 
HCMV activity we utilized a high throughput screening methodology (Fig. 1(a)), 95 
similar to the approach that we have previously used to screen siRNAs in HCMV 96 
infected cells [9]. Briefly, high passage HCMV strain AD169 and compounds from 97 
the GSK PIKS collection (listed in Table S1) were added to duplicate 384-well 98 
plates seeded with human foreskin fibroblast (HFF) cells. As negative and 99 
positive controls for compound treatment several wells in each plate were treated 100 
with either DMSO or heparan sulphate (a small molecule that inhibits HCMV 101 
entry into cells [10]), respectively. At 72 hours post infection (h.p.i.) cells were 102 
stained with Hoescht 33342 to detect nuclear DNA and CellMask to detect the 103 
area of the cell, plus were treated with antibodies to detect the cytoplasmic 104 
HCMV antigen pp28. An automated microscopy system was then used to assay 105 
both the number of cells in each well and the number of infected cells in each 106 
well expressing pp28. An image of infected cells treated as described above and 107 
captured using automated microscopy is shown in Fig. 1(b).  108 
The mean number of cells in each well per plate was determined. Where 109 
the number of cells in any well was less than 2-fold below the mean number of 110 
cells of the plate, the compound in that well was judged to be cytotoxic (listed by 111 
chemotype in Table 1 and by compound in Table S2). Data from the remaining 112 
wells on duplicate plates were combined and converted to a z-score (the number 113 
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of standard deviations from the mean of the data [11, 12]) to demonstrate the 114 
increase (positive z-score) or decrease (negative z-score) in the number of pp28 115 
positive cells in presence of each compound (shown in Fig. 1(c), listed by 116 
chemotype in Table 1 and by compound in Table S3).  117 
 118 
Analysis of cytotoxic compounds. We first investigated what 119 
compounds within chemotypes were judged to be cytotoxic. Approximately 40-120 
50% of compounds in the benzimidazole N-thiophene, 2H-3 pyrimidinyl 121 
pyrazolopyridazine, 3-amino pyrazolopyridines and 6-phenyl isoquinolines 122 
chemotypes contained compounds judged to be cytotoxic to HCMV infected cells 123 
(Table 1 and Table S2). Therefore, compounds from these chemotypes are 124 
generally not suitable for further use.  125 
We then utilized kinase selectivity data to investigate which kinase 126 
proteins were inhibited by each compound judged to be cytotoxic (Table S4). 127 
Kinase selectivity data [7] lists the ability of each compound to inhibit a panel of 128 
224 kinase proteins from several protein groups of the human kinome (including 129 
TK, STE, AGC, S-T-PK, CAMK and CMCG groups). We found that all cytotoxic 130 
benzimidazole N-thiophenes were potent inhibitors of PLK-1, whose inhibition 131 
can lead to apoptosis, and nearly all other cytotoxic compounds from a number 132 
of chemotypes were potent inhibitors of a range of CDK proteins, which are 133 
involved in regulation of the cell cycle. In our screen cytotoxicity was judged by 134 
the number of cells detected in each well of the screening plate. Therefore, we 135 
concluded that compounds were generally judged to be cytotoxic due to 136 
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apoptosis associated with inhibition of PLK-1 or due to lack of cell division 137 
associated with inhibition of CDK function.  138 
 139 
Analysis of compounds assigned z-scores. Next, we analyzed those 140 
compounds assigned z-scores to determine which compounds and chemotypes 141 
should be considered for further study as anti-HCMV compounds and chemical 142 
probes. We found that nearly all chemotypes contained compounds that had both 143 
positive and negative effects on pp28 production. Notably, however, the 2-aryl 3-144 
pyridimidinyl pyrazolopyridazine and furopyrimidine chemotypes and the 3-vinyl 145 
pyridine, 2,4-diamino pyrimidine, maleimide, phenyl carboxamide and indazole-5-146 
carboxamide chemotypes contained a large number of compounds with negative 147 
and positive effects on pp28 production, respectively (Tables 1 and S3). We 148 
sought to further characterize the results of our screen and judged any 149 
compound with a z-score between 1 to -1 to have little or no effect on pp28 150 
production, whereas compounds with z-scores of -1 to -2 and 1 to 2 had modest 151 
negative or positive effects on pp28 production, respectively. Thusly, compounds 152 
with z-scores of less than -2 or more than 2 had the greatest negative or positive 153 
effect on pp28 production, respectively. Therefore, three compounds 154 
(GW575808A, GW874091X and GW627512B) from three different chemotypes 155 
(2,4-diamino pyrimidines, imidazotriazines, 2-amino oxazoles, respectively) had 156 
strong positive effects on pp28 production, while four compounds (GW297361X, 157 
SB-734117, SB-220025-R and GW795493X) from four chemotypes (oxindoles, 158 
furazan benzimidazoles, 4-pyrimidinyl ortho-aryl azoles, furopyrimidines, 159 
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respectively) had strong negative effects on pp28 production (Figs. 1(c) and 160 
1(d)). 161 
 162 
Examination of kinase protein inhibition by compounds assigned z-163 
scores. We then examined kinase selectivity data of compounds assigned z-164 
scores (Table S5). The data from Table S5 is presented in Figure 2 as a 165 
³KHDWPDS´RINLQDVHLQKLELWLRQ. Nearly all compounds assigned z-scores exhibited 166 
polypharmacology and could inhibit more than one kinase protein. Consistent 167 
with our analysis of compounds judged to be cytotoxic (Table S2), we found that 168 
less than 5% of all compounds either potently inhibited PLK-1 or were potent 169 
inhibitors of several different CDK proteins (Table S5). Compounds with positive 170 
or negative z-scores were inhibitors of a wide range of kinase proteins in the TK 171 
kinase group (Fig. 2 and Table S5). Therefore, inhibition of TK kinases alone was 172 
unlikely to positivity or negatively influence pp28 production. However, a number 173 
of kinases in the STE (including MAP4K4 and MNK), CAMK (including PRKD1, 174 
PRKD2 and PRKD3) and CMCG (including CLK2, HIPK1, HIPK4, DYRK1A, 175 
DYRK1B, DYRK2) kinase groups were inhibited by compounds assigned z-176 
scores of less than -1 from 8, 4 and 3 different chemotypes, respectively (Figs. 177 
2(a)-(c), respectively, and Table S5). Therefore, these kinase proteins, alone or 178 
in combination, were likely to be important for HCMV replication and could 179 
represent future anti-HCMV drug targets. A number of compounds from two 180 
different chemotypes that inhibited kinases in AGC kinase family (including 181 
PRKG1, PRKG2, PRKX, PKA, ROCK1, ROCK2) were assigned z-scores over 1 182 
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(Fig. 2(d)). Therefore, these kinase proteins, alone or in combination, were likely 183 
to be inhibitory to HCMV replication. Compounds targeting these kinase proteins 184 
are likely to be off little value as anti-HCMV drugs.  185 
Compounds assigned z-scores of less than -2 (GW297361X, SB-734117, 186 
SB-220025-R and GW795493X) each had a distinct kinase selectivity profile 187 
(Fig. 2 and Table S5). Therefore, it was likely each compound inhibited pp28 188 
production by a different mechanism. Each was a potent inhibitor of several 189 
kinase proteins from several groups, except for SB-220025-R, which was a 190 
potent inhibitor of only 2 kinase proteins: CK1a and p38D (Fig. 2 and Table S5).  191 
Kinase inhibition of compounds assigned z-scores of greater than 2 was 192 
also examined. GW575808A and GW627512B had similar kinase selectivity 193 
profiles and were inhibitors of several TK and S-T-PK group kinases (Fig. 2 and 194 
Table S5). As inhibition of these TK and S-T-PK kinases can result in either 195 
positive or negative z-scores (Fig. 2 and Table S5), it was unlikely that inhibition 196 
of these TK and S-T-PK kinase proteins had a direct effect on pp28 production. 197 
Moreover, we found that GW874091X was not a potent inhibitor of any kinase 198 
assayed (Fig. 2 and Table S5). Therefore, GW874091X was either an inhibitor of 199 
kinase proteins not assayed in the kinase selectivity data or exerted an effect on 200 
pp28 production that did not involve inhibition of cellular kinase proteins. It, 201 
therefore, remains unclear from this analysis which kinase proteins should not be 202 
targeted in the development of future anti-HCMV drugs. 203 
We further considered the polypharmacology of compounds tested in our 204 
screen. It has been reported that ATP-competitive kinase inhibitors can inhibit the 205 
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function of proteins other than kinases, including aminergic GPCRs [6]. GPCR 206 
agonism and antagonism of the compounds in the GSK PKIS collection has been 207 
investigated elsewhere [7]. No compound within the GSK PKIS collection is a 208 
GPCR agonist, but several are GPCR antagonists [7]. However, we observed no 209 
correlation between compounds judged to be cytotoxic, compounds assigned a 210 
z-score and GPCR antagonism (data not shown).  211 
 212 
Inhibition of HCMV replication by SB-734117. We chose to focus our 213 
studies on SB-734117, a compound from the furazan benzimidazole chemotype 214 
that had a low z-score in our screen (Figs. 1(c) and 1(d)). First, we used viral 215 
yield reduction assays to assess the ability of SB-734117 to inhibit replication of 216 
HCMV strain AD169 compared to the frontline anti-HCMV drug ganciclovir (GCV) 217 
(Table 2, experiment 1) at up to 96 h.p.i. The 50% effective dose (ED50) of both 218 
SB-734117 and GCV was 0.5PM, indicating that SB-734117 inhibit AD169 219 
replication as efficiently as the current frontline anti-HCMV drug. To complement 220 
and confirm this data we analyzed AD169 replication over time and found an 221 
approximately 2-fold decrease in AD169 replication from 72-96 h.p.i. in the 222 
presence of 1PM SB-734117 (Fig. 3(a)).  223 
We also found that SB-734117 could inhibit replication of a ganciclovir 224 
resistant virus (AD169-P53) and a low passage HCMV strain 225 
(Merlin(RCMVR1111)), whose genomic content is similar to a clinical sample 226 
[13], at low or sub-micromolar ED50 values (Table 2, experiments 2 and 3, 227 
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respectively) at up to 96 h.p.i.. Therefore, SB-734117 was an effective inhibitor of 228 
different HCMV strains.  229 
To ensure that the anti-HCMV activity of SB-734117 was not due to 230 
cellular cytotoxicity we used an MTT dye-uptake assay to assess cell viability and 231 
cell division in uninfected cells in the presence of SB-734117. We found that the 232 
50% cellular cytotoxicity (CC50) of SB-734117 after 96 hours treatment with SB-233 
734117 was greater than 10PM (data not shown). Thus, the CC50 values in 234 
uninfected cells were greater than 10PM at the ED50 values for all HCMV strains 235 
tested. Therefore, inhibition of HCMV replication by SB-734117 observed in 236 
experiments shown in Table 2, or in the other experiments presented here, was 237 
unlikely to be the result of cellular cytotoxicity or inhibition of cell division. 238 
 239 
Examination of HCMV immediate early protein and mRNA production 240 
in HCMV infected cells treated with SB-734117. We next sought to understand 241 
how HCMV replication was inhibited by SB-734117. Therefore, western blotting 242 
was used to analyze the accumulation of HCMV proteins in the presence or 243 
absence of SB-734117 (Fig. 3(b)). Compared to treatment of infected cells with 244 
DMSO (Fig. 3(b), lanes 2-4), the treatment of infected cells with SB-734117 (Fig. 245 
3(b), lanes 5-7) reduced the accumulation of immediate early proteins IE1 and 246 
IE2, and IE2 proteins expressed late in infection (IE2-60 and IE2-40 [14]). In this 247 
and subsequent western blots the amount of E-actin in each sample was also 248 
assayed, which demonstrated equivalent loading of samples in each lane.  249 
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We then quantified the relative density of the western blotting bands 250 
shown in Fig. 3(b), by determining the band intensity of bands corresponding to 251 
viral proteins relative to the intensity of the E-actin band in the same lane (Fig. 252 
3(c)). We found an approximately 2-4 fold decrease in the accumulation of IE1 in 253 
the presence of 1 PM SB-734117, which is consistent with an ED50 of 0.5-1 PM 254 
shown in Table 2. The loss of IE2 protein production (approximately 2- to 20-fold, 255 
depending on which antibody was used (Fig. 3(c))) was greater than IE1. 256 
Consistent with loss of IE protein production and our screening results, we also 257 
observed using western blotting that treatment of cells with SB-734117 resulted 258 
reduced accumulation of the HCMV early and late proteins UL44 and pp28, 259 
respectively, compared to infected cells treated with DMSO (data not shown). To 260 
compliment these findings we assayed for differences in IE1 and IE2 mRNA 261 
expression in infected cells treated with SB-734117 compared to infected cells 262 
treated with DMSO using quantitative PCR against the two major IE RNA species 263 
(Fig. 3(d)). This analysis revealed that no obvious defect in IE1 mRNA levels was 264 
evident in the presence of SB-734117. The analysis of IE2 mRNA again did not 265 
show any overt phenotype although typically a 2 fold reduction in IE2 mRNA was 266 
observed in SB-734117 treated cells when compared with DMSO control.  267 
However, taken together the data suggest that the decrease in IE1 and IE2 268 
protein production shown in Figs. 3(b) and 3(c) was unlikely to be the result of 269 
decreased IE gene expression.  270 
Our studies thus far could not rule out that SB-734117 impacted events 271 
occurring prior to IE gene expression. Thus we addressed whether the presence 272 
 13 
of SB-734117 may affect virus entry into the cell or translocation of the HCMV 273 
genome to the nucleus. Pre-exposure of cells to SB-734117 before infection or 274 
incubation of virus with SB-734117 before infection did not increase the inhibitory 275 
effects of the compound (data not shown). However, when we treated AD169 276 
infected HFF cells with 1PM SB-734117 at 24 h.p.i. we found a 2-fold decrease in 277 
HCMV replication at 120 h.p.i., compared to infected cells treated with DMSO at 278 
24 h.p.i. (Fig. 4(a)). Quantitative analysis of western blotting of infected cells 279 
treated as described above (Figs 4(a) and 4(b)) showed that, similar to data 280 
presented in Fig. 3, treatment of infected cells with SB-734117 resulted in 281 
approximately 2-fold decrease in IE2 protein production depending on which 282 
antibody was used. However, there was no obvious decrease in production of 283 
IE1 protein.  284 
Therefore, SB-734117 had no obvious effect on cells or virus before 285 
infection, but could inhibit HCMV replication after entry of the HCMV genome and 286 
did so by reducing IE2 protein production. Thus, SB-734117 may not inhibit 287 
events during infection before expression of IE proteins, but could have inhibitory 288 
effects on HCMV replication after the initiation of IE protein production.  289 
 290 
Inhibition of AGC and CMCG kinase proteins by SB-734711. Next, we 291 
investigated what kinases proteins are inhibited by SB-734117. SB-734117 has 292 
been reported to inhibit MSK1 [15]. However, using the kinase selectivity data 293 
shown in Fig. 2 and Table S5, we found that at SB-734117 inhibits several AGC 294 
kinase group proteins, including MSK1 (MSK1, MSK2, RSK1, RSK2, RSK3, 295 
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p70S6K1, PCK-Ș, PRKG2, ROCK1, ROCK2), and several CMCG kinase group 296 
proteins (GSK3A, GSK3B, DYRK1A and DYRK1B). However, in our screen 297 
potent and selective inhibitors of GSK3A and GSK3B had no obvious negative 298 
effect on pp28 production (Table S5) and compounds with either positive or 299 
negative z-scores were potent inhibitors of PKC-Ș, PRKG2, ROCK1 and ROCK2 300 
(Table S5). Therefore, inhibition of these kinases proteins may not be related to 301 
inhibition of pp28 production. Rather, analysis of SB-734117 kinase selectivity 302 
data compared to other assigned z-scores argued that potent inhibition of MSK1, 303 
MSK2, RSK1, RSK2, RSK3, p70S6K1, DYRK1A and DYRK1B was related to 304 
inhibition of pp28 production.  305 
 A kinase inhibitor that is structurally unrelated to SB-734117, H-89, inhibits 306 
a similar range of AGC and CMCG kinase proteins [16]. We found that H-89 307 
inhibited productive HCMV replication and immediate-early protein production 308 
(data not shown). Therefore, inhibition of AGC and CMCG kinase proteins, not 309 
an unknown function of SB-734117, is likely to be responsible for the observed 310 
defects in HCMV replication and protein production. Furthermore, using western 311 
blotting [17], we found that SB-734117 did not inhibit autophosphorylation of the 312 
HCMV encoded kinase UL97 (data not shown). Therefore, the anti-HCMV effects 313 
of SB-734117 were unlikely to be due to inhibition of UL97.  314 
 315 
Analysis of CREB and histone H3 phosphorylation in HCMV infected 316 
cells. We then considered how inhibition of AGC and CMCG kinase proteins by 317 
SB-734114 would affect post-translational modification of cellular proteins 318 
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thought to be involved in HCMV replication. We focused our investigation on 319 
phosphorylation of the cellular transcription factor CREB and histone H3.  320 
CREB is thought to directly or indirectly facilitate transcription from the 321 
MIEP [18, 19] and other viral promoters [20] during productive HCMV replication 322 
and it has been reported that phosphorylation of CREB at serine residue 133 323 
(CREB-Ser133) by MSK1 is involved in promoting changes to chromatin required 324 
for activation of the MIEP during HCMV reactivation from latency [21]. In 325 
preliminary experiments we could not detect either total cellular CREB or CREB-326 
Ser133 before 72 h.p.i. using western blotting (data not shown). However, both 327 
proteins could only be detected at 72 h.p.i. when we increased the amount of cell 328 
lysate assayed (see Materials & Methods). Therefore, we used western blotting 329 
to assay total cellular CREB and CREB-Ser133 phosphorylation in HCMV 330 
infected cells treated with either DMSO or SB-734117 at 72 h.p.i. (Fig. 5(a)). We 331 
observed a decrease in accumulation of CREB-Ser133 and an increase in the 332 
accumulation of CREB in the presence of SB-734117 (Fig. 5(a), lane 5), 333 
compared to infected cells treated with DMSO (Fig. 5(a), lane 3). Analysis of 334 
relative band intensities (Fig. 5(b)), indicated that there was approximately a 2-335 
fold decrease in CREB-Ser133 in infected cells treated with SB-734117, 336 
compared to those treated with DMSO and a modest increase in CREB. The 2-337 
fold decrease in the accumulation of CREB-Ser133 in the presence of 1PM SB-338 
734117 was consistent with the observed ED50 of 0.5-1 PM and 2-4 fold 339 
decrease in production of immediate-early HCMV protein production (Table 2 340 
and Fig. 3). Therefore, the effect of SB-734117 on HCMV replication correlated 341 
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with a loss of CREB-Ser133 phosphorylation. Similar observations were made 342 
when infected cells were treated with H89 (data not shown), indicating the AGC 343 
and CMCG kinase proteins were involved in phosphorylation of CREB. 344 
Phosphorylation of histone H3 by MSK1 or another kinase, IKKD  is 345 
required for binding of transcription factors to DNA in uninfected cells [22, 23]. 346 
We have previously demonstrated that phosphorylation of histone H3 at serine 347 
residue 10 (H3S10p) by IKKD is associated with immediate-early protein 348 
production during productive HCMV replication [17]. Also, it has been 349 
demonstrated that H3S10 phosphorylation by MSK1 is associated with 350 
immediate-early gene expression during reactivation of HCMV from latency [21]. 351 
We decided to assay H3S10 phosphorylation in the presence of SB-734117. 352 
Using western blotting we analyzed accumulation of H3 and H3S10 353 
phosphorylation in uninfected HFF cells (Fig. 5(c), lane 1) and AD169 infected 354 
HFF cells treated with either DMSO or SB-734117 (Fig. 5(c), lanes 2-4 and 5-7, 355 
respectively, at 24-72 h.p.i.). Similar levels of H3 were found in each sample, 356 
however, over time we observed a decrease in H3S10p in infected cells treated 357 
with SB-734117 to near undetectable levels, compared to infected cells treated 358 
with DMSO. Therefore, inhibition of H3S10 phosphorylation during productive 359 
HCMV replication may have contributed to the anti-HCMV activity of SB-734117. 360 
Similar results were found when infected cells were treated with H89 (data not 361 
shown), indicating that AGC and CMCG kinase proteins were involved in 362 
phosphorylation of H3S10.  363 
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Phosphorylation of histone H3 at serine residue 28 (H3S28) by MSK1 is 364 
also known to be associated with gene expression in uninfected cells [22]. We 365 
also used western blotting to investigate H3S28 phosphorylation during HCMV 366 
replication. However, we could not detect H3S28p in either uninfected HFF cells, 367 
AD169 infected HFF treated with either DMSO or SB-734117, or uninfected HFF 368 
cells treated with either anisomycin, which can stimulate H3S28 phosphorylation, 369 
or phosphatase inhibitor okadaic acid, which can prevent dephosphorylation of 370 
histones (data not shown). Therefore, we suggest that inhibition of H3S28 371 
phosphorylation did not contribute to the anti-HCMV activity of SB-734117. 372 
 373 
Analysis of histone H3 post-translational modifications in HCMV 374 
infected cells. H3S10 phosphorylation by either MSK1 or IKKD is associated 375 
with the presence of acetyl modifications of H3, including at acetylation (ac) of 376 
lysine 14 (H3K14ac) [24-26]. There is a relationship during transcriptional 377 
activation between the presence of H3S10p and H3K14ac and the association of 378 
transcription factors with DNA [23, 27]. As the presence of H3K14ac is 379 
associated with transcriptional activation in HCMV infected cells [28], H3K14ac 380 
may be required for HCMV replication. We have previously demonstrated that 381 
during HCMV replication inhibition or depletion of IKKD leads to loss of total 382 
cellular H3S10 phosphorylation, but not loss of total cellular H3K14ac [17]. Thus, 383 
we assayed whether treatment of HCMV infected cells by SB-734117 would lead 384 
to loss of H3S10p or H3K14ac. We used western blotting to assay total cellular 385 
levels of H3, H3S10p and acetylation of H3 on a number of commonly studied H3 386 
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lysine residues including K14 (H3K9ac, H3K14ac, H3K18ac, H3K27ac) in either 387 
uninfected HFF cells (Fig. 5(c), lane 1) or HFF cells infected with HCMV and 388 
treated with either DMSO or SB-734117 (Fig. 5(c), lanes 2-4 and 5-7, 389 
respectively). Treatment of infected cells with SB-734117 had a slight effect (less 390 
than 2-fold (data not shown)) on accumulation of H3K14ac and no detectable 391 
effect on detection of H3K9ac, H3K18ac, or H3K27ac. Therefore, treatment of 392 
infected cells with SB-734117 was associated with loss of total cellular H3S10p, 393 
but not loss of the total cellular H3 acetylation modifications we assayed, 394 
including H3K14ac.  395 
The relationship between H3S10p and dimethylation (me2) and 396 
trimethylation (me3) of H3 and H3 phosphorylation is not well characterized, but 397 
it has been reported that in a murine model there is a relationship between the 398 
presence of H3S10p and the presence of H3K36me3 [29] and in Drosophila 399 
melanogaster loss of the MSK1/2 homologue JIL-1 results in loss of H3S10p, H3 400 
acetylation and H3 methylation, including H3K36me3 [30]. Therefore, we asked if 401 
loss of total cellular H3S10p in HCMV infected cells was associated with me2 402 
and me3 modification of H3 lysine residues. Western blotting was used to assay 403 
the presence of H3 and H3S10p, plus me2 (H3K4me2, H3K27me2, H3K36me2) 404 
or me3 (H3K4me3, H3K9me3, H3K27me3, H3K36me3) modifications of H3 in 405 
uninfected HFF cells (lane 1, Figs. 5(d) and 5(e), respectively) or HFF cells 406 
infected with HCMV and treated with either DMSO or SB-734117 (lanes 2-4 and 407 
5-7, Figs. 5(d) and 5(e), respectively). We observed that SB-734117 had no 408 
effect on total cellular accumulation of any me2 modification of H3 (Fig. 5(d)) or 409 
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accumulation of H3K4me3, H3K9me3 or H3K27me3 (Fig. 5(e)).  However, we 410 
observed a near total loss of detectable H3K36me3 over time in infected cells 411 
treated with SB-734117 (Fig. 5(e), lane 7) compared to infected cells treated with 412 
DMSO (Fig. 5(e), lane 4). Similarly, a near total loss of detectable H3K36me3 413 
was observed in infected cells treated with H89 (data not shown), suggesting that 414 
loss of H3K36me3 is related to inhibition of AGC and CMCG kinase proteins. 415 
Thus, inhibition of H3K36me3 was associated with loss of total cellular H3S10p 416 
and was likely the result of inhibition of AGC and CMCG kinase proteins inhibited 417 
by SB-734117. Loss of both total cellular H3S10p and total cellular H3K36me3 418 
may have contributed to the anti-HCMV activity of SB-734117.  419 
 420 
Investigation of HCMV MIEP transcriptional activation.  Loss of CREB 421 
and H3S10 phosphorylation (Figs. 5(a)-(e)) suggested that SB-734117 acted by 422 
inhibiting activation of the HCMV MIEP. However, our analysis of IE1 and IE2 423 
gene expression (Fig. 3(d)) indicated that transcription from the MEIP was not 424 
obviously compromised in the presence of SB-734117. To investigate this in 425 
more detail we utilized chromatin immunoprecipitation (ChIP) to assay the 426 
presence of H3K14ac, a marker of MIEP transcriptional activation [28], at the 427 
MIEP in the presence of either DMSO or SB-734117 (Fig. 6). The data showed 428 
that no overt impact on H3K14ac at the MIEP between 24-72hpi in DMSO or SB-429 
734117 treated cells. Indeed, we noted that SB-734117 treated cells actually 430 
showing higher levels of H3K14ac at the MIEP at late times post infection when 431 
compared to control. Therefore, in agreement with our analysis of IE1 and IE2 432 
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gene expression (Fig. 3(d)), there was no obvious defect in MIEP transcriptional 433 
activation in the presence of SB-734177. Thus, the observed defects in HCMV 434 
immediate-early protein production (Figs 3 and 4) could not be explained by 435 
defects in transcription from the MIEP.   436 
 437 
  438 
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DISCUSSION 439 
  440 
Our overall analysis of the chemotypes screened indicated that each 441 
chemotype contained compounds with anti-HCMV activity, however modest that 442 
anti-HCMV activity may have been. As the structure of each compound in each 443 
chemotype is known, structure-activity relationships derived from our data could 444 
form the basis of future studies in the discovery of compounds with anti-HCMV 445 
activity from each chemotype. 446 
Our survey of the GSK PKIS kinase selectivity data argued that several 447 
proteins from several kinase groups, alone or in combination, were required for 448 
pp28 production. These proteins kinases include those from the STE (including 449 
MAP4K4 and MNK), CAMK (including PRKD1, PRKD2 and PRKD3) and CMCG 450 
(including CLK2, HIPK1, HIPK4, DYRK1A, DYRK1B, DYRK2) kinase groups. 451 
The function of these protein kinases in productive HCMV replication is unclear 452 
or unknown. Therefore, it is possible that our data identified novel cellular factors 453 
required for productive HCMV replication. However, the polypharmacology of the 454 
compounds tested makes it difficult to identify specific kinases required for 455 
productive HCMV replication. Thus, each of the aforementioned kinases will have 456 
to be tested individually to identify their roles in HCMV infected cells. With this 457 
information these kinases could be exploited as novel anti-HCMV drug targets. 458 
We chose to pursue studies of SB-734117 as this compound had one of 459 
the greatest negative effects on pp28 production in our screen, with no obvious 460 
cytotoxic effects, and was an effective inhibitor of a number of HCMV strains. 461 
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Moreover, the function of the AGC and CMCG kinase proteins inhibited by SB-462 
734117 in productive HCMV replication was unknown or unclear.  463 
SB-734117 was originally described as an inhibitor of MSK1 [15]. 464 
However, like other MSK1 inhibitors [16], SB-734117 displays polypharmacology 465 
and can inhibit several kinases whose roles in productive HCMV replication are 466 
unknown or unclear. Thus, to understand how SB-734117 inhibits HCMV 467 
replication it will be necessary to understand if a particular kinase or a 468 
combination of kinase proteins is required for productive HCMV replication. A 469 
truly selective inhibitor of MSK1 has yet to be found. Structure-activity 470 
relationships involving SB-734117 and other furazan benzimidazole compounds 471 
could be explored to generate compounds with improved anti-HCMV activity and 472 
kinase selectivity. However, we could discern no obvious relationship between 473 
inhibition of HCMV replication, kinase selectivity and the structures of 474 
compounds within the furazan benzimidazole chemotype analyzed here due to 475 
the small number of furazan benzimidazole compounds that returned low 476 
negative z-scores in our screen (data not shown). An improved compound 477 
related to SB-734117 would have value as an anti-HCMV drug, as it would have 478 
the potential to inhibit both productive HCMV replication and reactivation of 479 
HCMV from latency. Plus, based on our observations, an improved compound 480 
should be as effective an inhibitor of HCMV replication as ganciclovir and be able 481 
to inhibit replication of ganciclovir resistant HCMV strains.  482 
 Perhaps the most intriguing observations we make concern modification of 483 
histone H3 in the presence of SB-734117. Previous observations from our 484 
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laboratory have indicated that IKKD was required for H3S10 phosphorylation in 485 
AD169 infected HFF cells [17], which is consistent with data presented 486 
elsewhere indicating that H3S10 is substrate of IKKD [24, 25, 31-33]. We note 487 
that inhibition of IKKD results in loss of H3S10p early in HCMV replication (24 488 
h.p.i. onwards) [17], whereas treatment with SB-734117 leads to a loss of 489 
H3S10p later in HCMV replication (48-72 h.p.i.). SB-734117 does not inhibit 490 
IKKD(Table S5). Therefore, we propose that in HCMV infected cells a 491 
mechanism exists wherein IKKD does not phosphorylate H3S10 during treatment 492 
with SB-734117. Conversely, kinases inhibited by SB-734117 do not 493 
phosphorylate H3S10 when IKKD is inhibited or depleted. This mechanism may 494 
ensure appropriate regulation of H3S10 phosphorylation that is necessary for 495 
productive HCMV replication.  496 
 It has been reported that in uninfected cells from humans and mice loss of 497 
H3S10p can lead to loss of H3K14ac [24-26]. However, we did not observe loss 498 
of total cellular H3K14ac upon treatment of HCMV infected cells with SB-734117 499 
or in our previous study where inhibition or depletion of IKKD resulted in loss of 500 
H3S10p [17]. We speculate, as we have done previously [17], that an as yet 501 
unrecognized mechanism exists in HCMV infected cells that maintains total 502 
H3K14ac when total H3S10p levels are lowered to near undetectable levels.  503 
 We observed that treatment of HCMV infected cells with SB-734117 504 
resulted in loss of H3K36me3. We have previously found that depletion of IKKD 505 
in HCMV infected cells leads to loss of H3S10p, but not H3K36me3 [17]. 506 
Therefore, the loss of H3K36me3 in HCMV infected cells is related to loss of 507 
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H3S10p during inhibition of AGC and CMCG kinases, but not during inhibition of 508 
IKKDThis may be related to regulation of H3S10 phosphorylation by different 509 
kinases, as we discuss above. We propose that, as in mice and Drosophila [29, 510 
30], the presence of H3K36me3 in HCMV infected cells is related to the presence 511 
of H3S10p, potentially via phosphorylation of H3 by MSK1. Alternatively, there 512 
may be a substrate of kinase proteins inhibited by SB-734117 whose 513 
phosphorylation directly or indirectly mediates H3K36 tri-methylation.  514 
Treatment of HCMV infected cells with SB-734117 impacted on immediate 515 
early protein production and caused loss of total cellular levels of post-516 
translational modification of cellular factors potentially involved in transactivation 517 
of the HCMV MIEP. However, in the presence of SB-734117 we did not find 518 
obvious defects in activation of transcription from the HCMV MIEP or defects in 519 
immediate-early gene transcription. Therefore, the loss of total cellular levels of 520 
CREB and H3S10 phosphorylation or H3K36me3 had no direct impact on 521 
transcription from the HCMV MIEP. This interpretation would be consistent with 522 
previous studies that have shown that the deletion of CREB binding sites from 523 
the MIEP has little impact on productive HCMV replication [21, 34]. During 524 
reactivation, it is hypothesized the H3S10p is important as it drives the transition 525 
of the MIEP from a repressed to active promoter, a mechanism also proposed for 526 
HSV reactivation [35] Thus, during productive HCMV replication at high MOI, 527 
where the MIEP is associated with active, not repressed, chromatin very early 528 
post infection [28], H3S10p may not be essential for transcription. However, it 529 
remains possible that H3S10p has a role in the release of Early and Late HCMV 530 
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promoters from repression as infection proceeds. Thus, future challenges will 531 
include mapping of CREB, H3S10p and H3K36me3 to viral and cellular 532 
promoters to understand in more detail to understand their possible involvement 533 
in productive HCMV replication.  534 
We propose that the greatest impact of SB-734117 on productive HCMV 535 
replication is on production of IE proteins. It will be important to investigate if SB-536 
734117 impacts on additional phosphorylation events that are required for 537 
production of both proteins. Post-translational modification of both IE1 and IE2 is 538 
not yet completely characterized. Thus, SB-734117 could directly or indirectly 539 
inhibit phosphorylation of these proteins, which leads to their loss. Further 540 
investigation of IE protein production and the roles of IE post-translational 541 
modification are required in order to fully understand the mechanism of action of 542 
SB-734117 during productive HCMV replication.  543 
  544 
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MATERIALS & METHODS 545 
 546 
Compounds. The GSK PIKS library (version 1) was supplied to the Institute of 547 
Chemistry and Chemical Biology-Longwood at Harvard Medical School by GSK. 548 
SB-734117 was a kind gift from GlaxoSmithKline. Ganciclovir was obtained from 549 
SIGMA. H89 and heparan sulphate were obtained from Calbiochem. All drugs 550 
were resuspended in dimethyl sulfoxide (DMSO).  551 
 552 
Cells and viruses. Human foreskin fibroblast (HFF) cells (clone Hs29) were 553 
obtained from American Type Culture Collection no. CRL-1684 (ATCC, 554 
Manassas, VA) and maintained in Dulbeccos Modified Eagles Medium (DMEM) 555 
(Gibco) containing 5% fetal bovine serum (FBS) (Gibco), plus penicillin and 556 
streptomycin. High passage HCMV strain AD169 was a gift from Don Coen 557 
(Harvard Medical School). Low passage strain Merlin R1111 (derived from 558 
BACmid pAL1111, which does not express RL13 and UL128)[36] was a gift from 559 
Richard Stanton (Cardiff University). Ganciclovir resistant virus AD169-P53 was 560 
supplied by the National Institute of Health (NIH) AIDS Reagent Program.  561 
 562 
Screening of GSK PKIS collection and analysis of screening data. See 563 
supplementary material.  564 
 565 
Characterization of compounds within the GSK PKIS collection. See 566 
supplementary material.  567 
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 568 
Viral yield reduction assays.  Assays were performed essentially as described 569 
in [37]. HFF cells were plated at 5 × 104 cells per well in 24-well plates. After 570 
overnight incubation, cells were infected with HCMV at a multiplicity of infection 571 
(MOI) of 1. After virus adsorption for 1 hour at 37°C, cells were washed and 572 
incubated with 0.5 ml of media containing DMSO or compounds at a range of 573 
concentrations in duplicate. Plates were incubated for 4 days at 37°C. Titers 574 
were determined by serial dilution of viral supernatant onto HFF monolayers 575 
which were covered in DMEM containing 5% FBS, 0.6% methylcellulose and 576 
antibiotics. Cultures were incubated for 14 days, cells were stained, with crystal 577 
violet and plaques were counted. Data shown represents the mean value of 578 
duplicate plaque counts. The final concentration of DMSO in all samples was 579 
maintained at <1% (v/v).  580 
 581 
MTT cytotoxicity assays. Assays were performed essentially as described [37]. 582 
HFF cells were seeded at 1 × 104 cells per well into 96-well plates. After 583 
overnight incubation to allow cell attachment, cells were treated for the time 584 
indicated in the text with at range of concentrations concentrations in duplicate. 585 
The highest concentration of compound tested was 10 PM. Cell viability was then 586 
determined with an MTT assay according to the manufacturer's instructions (GE 587 
Healthcare). Data shown represents the mean value of duplicate readings. The 588 
final concentration of DMSO in all samples was maintained at <1% (v/v). As a 589 
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positive control, in all experiments a 2-fold dilution series of HFF cells starting at 590 
1 × 104 cells per well was included. In each experiment we found a linear 591 
relationship between the number of cells per well and output from the MTT assay 592 
(data not shown).  593 
 594 
Western blotting. At time points indicated in the text cells were washed 595 
once with PBS and resuspended in 100 Pl Laemmli buffer containing 5% E-596 
mercaptoethanol. Proteins were separated on 8% or 10% polyacrylamide gels. 597 
Typically, a volume of cell lysate corresponding to 1 x 104 HFF cells was 598 
analyzed, except when blotting for CREB or CREB-Ser133 when a volume of cell 599 
lysate corresponding to 5 x 105 HFF cells was analyzed. Antibodies used are 600 
listed in the supplementary material. Relative band intensity (band intensity 601 
relative to E-actin signal in the same lane) was analyzed using ImageJ software, 602 
obtained from the National Institutes of Health (USA). 603 
 604 
RNA analysis and Quantitative PCR.  Quantitative PCR was performed 605 
using a SYBR green qPCR kit (Qiagen) and analysed using the ''CT method to 606 
compare DMSO versus SB-734117 treated cells. Briefly, cDNA was prepared 607 
from RNA extracted from infected cells at timepoints indicated in the Figure. 608 
cDNA and no RT controls were amplified in technical duplicates from multiple 609 
experiments using a constant primer in exon 3 (UL122-123) and a primer from 610 
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exon 4 (UL123) or exon 5 (UL122). Cellular RNA was amplified using 18S RNA 611 
primers. 612 
Exon 3:  ACG AGA ACC CCG AGA AAG ATG; exon 4: CGC CAG TGA ATT 613 
TCT CTT C; exon 5: CCG GGG AGA GGA GTG TTA GT; 18S for: GTA ACC 614 
CGT TGA ACC CCA; 18S rev: CCA TCC AAT CGG TAG TAG CG.  615 
qPCR was performed using cycling conditions: 95oC (15s) then 40 cycles of 94oC 616 
(15s), 55oC (30s) and 72oC (30s). 617 
 618 
Chromatin immunoprecipitation. All procedures were performed 619 
essentially as previously described [21]. Briefly, HFFs were fixed with 1% 620 
formaldehyde (10 mins) and then enzymatically digested to fragment DNA as 621 
described by manufacturer (Pierce chromatin preparation kit). DNA associated 622 
with histones was immunoprecipitated with control serum (Sigma) or anti-acetyl-623 
histone H3-lysine 14 (1:150 dilution of antibody ± see supplementary material). 624 
For detection of the HCMV MIEP, DNA from disrupted nucleosomes was 625 
precipitated and amplified by SYBR green qPCR kit (Qiagen) using 5′- TGG 626 
GAC TTT CCT ACT TGG (sense) and 5′- CCA GGC GAT CTG ACG GTT (anti-627 
sense) primers. Specific immuno-precipitation of sequences was expressed as 628 
enrichment from Input. 629 
  630 
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ABBREVIATIONS 647 
 648 
AGC: containing PKA, PKG, PKC families group, CAMK: calcium/calmodulin-649 
dependent protein kinase group, CDK: cyclin-dependent kinase, CLK2: cyclin-650 
dependent kinase-like kinase 2, CK: casein kinase, CMCG: containing CDK, 651 
MAPK, GSK3, CLK families group, CREB: cAMP response element-binding 652 
protein, GCV: ganciclovir, DYRK: dual-specificity tyrosine phosphorylation-653 
regulated kinase, GSK: glycogen synthase kinase, HCMV: human 654 
cytomegalovirus, HIPK: homeodomain interacting protein kinase, MAPK4K4: 655 
mitogen-activated protein kinase kinase kinase kinase 4, MNK1: MAP kinase-656 
interacting serine/threonine-protein kinase 1, MSK: mitogen and stress kinase, 657 
PCK-Ș: protein kinase C-Ș, PLK-1: polo-like kinase 1, PRKD: protein kinase D, 658 
PRKG: protein kinase, cGMP-Dependent, PRKX: protein kinase, x-linked, 659 
p70S6K1: ribosomal protein S6 kinase beta-1,  ROCK: rho-associated, coiled-660 
coil-containing protein kinase 1,  RSK: ribosomal s6 kinase, STE: homologs of 661 
yeast Sterile 7, Sterile 11, Sterile 20 kinases group, S-T-PK: serine/threonine 662 
protein kinase group, TK: tyrosine kinase group, TKL: tyrosine kinase-like group. 663 
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 781 
FIGURE LEGENDS 782 
 783 
Fig. 1 High throughput screening of the GSK PKIS collection. (a) Diagram of 784 
screening process. (b) A representative example of a microscopy image from an 785 
Image Express Micro microscope of infected HFF cells treated with Hoecsht 786 
33342 (blue), Deep Red Cell Mask (Red) and primary and secondary antibodies 787 
to detect HCMV pp28 (green). The large white box is a magnified image of the 788 
area identified by the small white box. (c) Plot of z-scores where each data point 789 
represents a single compound. The compounds with highest and lowest z-scores 790 
are identified and their z-scores are stated in parentheses. (d) Structures of 791 
compounds with z-scores ((i)-(iv)) lower than -2 and ((v)-(vii)) greater than 2. 792 
 793 
Fig. 2 Kinase selectivity of compounds assigned z-scores. The full list of 794 
kinase selectivity data is shown in Table S5. Table S5 is shown here as a 795 
³heatmap´ of kinase selectivity wherein the potency of each compound at 1 PM 796 
concentration against a particular kinase is represented in colour as indicated at 797 
the bottom of the figure (less than 0% inhibition ± blue, 0-50% inhibition ± green, 798 
51-75% inhibition ± yellow, 76-90% inhibition ± orange, greater than 91% 799 
inhibition ± red). Each row represents a compound and each column represents 800 
the kinase tested. The z-scores of each compound are indicated to the left of the 801 
figure. The kinase groups of each kinase tested are indicated above the figure. 802 
(a)-(c) Kinase inhibition of compounds with z-scores of less than -1 not found in 803 
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compounds with z-scores greater than 1. (d) Kinase inhibition of compounds with 804 
z-scores greater than 1 not found in compounds with z-scores of less than -1. 805 
 806 
Fig. 3 Analysis of HCMV replication and protein production in infected HFF 807 
cells treated with DMSO or SB-734117 at the time of infection. (a) HFF cells 808 
were infected at MOI1 with AD169 then treated with 1PM SB-734117 or the 809 
equivalent volume of DMSO. Viral titre (plaque forming units (p.f.u.)/ml)) was 810 
determined at the indicated time points (hours post infection (h.p.i.)). Data points 811 
and error bars represent the mean and standard deviation, respectively, from 812 
three experiments. (b) HFF cells were infected with AD169 at an MOI of 1, then 813 
treated with either 1PM SB-734117 or the equivalent volume of DMSO. Cell 814 
lysates were prepared for western blotting at the time points (hours post infection 815 
(h.p.i.)) indicated above the figure. Uninfected cells harvested at the time of 816 
infection are shown as 0 h.p.i.. Proteins recognized by the antibodies used are 817 
indicated to the right of each figure. The positions of molecular mass markers 818 
(kDa) are indicated to the left of each figure. (c) Relative band intensity of 819 
immediate-early protein bands relative to E-actin signal in the same lane in 820 
Figure 3A, as quantified using ImageJ. Band intensities of 0-1, 1-2 and greater 821 
than 2 are highlighted in light grey, dark grey and black, respectively. (d) HFF 822 
cells were infected at MOI1 with AD169 then treated with 1PM SB-734117 or the 823 
equivalent volume of DMSO. Samples were prepared for quantitative PCR 824 
analysis of IE1 and IE2 mRNA expression, respectively, at the time points 825 
indicated in the figures. Data and error bars represent the mean and standard 826 
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deviation of three PCR replicates from each sample, respectively (n=2). Change 827 
in gene expression relative to DMSO is shown for each timepoint using ''CT 828 
method. 829 
 830 
Fig. 4 Analysis of HCMV replication and protein production in infected HFF 831 
cells treated with DMSO or SB-734117 at 24 hours post infection. (a) HFF 832 
cells were infected at MOI1 with AD169 then treated with 1PM SB-734117 or the 833 
equivalent volume of DMSO at 24 hours post infection. Viral titre (plaque forming 834 
units (p.f.u.)/ml)) was determined at 120 hours post infection (h.p.i.). (b) HFF 835 
cells were infected with AD169 at an MOI of 1, then treated with either 1PM SB-836 
734117 or the equivalent volume of DMSO at 24 hours post infection. Cell 837 
lysates were prepared for western blotting at the time points (hours post infection 838 
(h.p.i.)) indicated above the figure. Infected cells harvested at 24 h.p.i. that were 839 
not treated with either SB-734117 or DMSO were also assayed. Proteins 840 
recognized by the antibodies used are indicated to the right of each figure. The 841 
positions of molecular mass markers (kDa) are indicated to the left of each figure. 842 
(c) Relative band intensity of immediate-early protein bands relative to E-actin 843 
signal in the same lane in Figure 3A, as quantified using ImageJ. Band intensities 844 
of 0-1, 1-2 and greater than 2 are highlighted in light grey, dark grey and black, 845 
respectively.  846 
 847 
Fig. 5 Inhibition of phosphorylation of cellular proteins by SB-734117 ((a), 848 
(c)-(3)) HFF cells were infected with AD169 at an MOI of 1, then treated with 849 
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either 1PM SB-734117 or the equivalent volume of DMSO (as indicated above 850 
each Figure). Cell lysates were prepared for western blotting at (a) 72 h.p.i. or 851 
((c)-(e)) as indicated above the figure. Uninfected cells harvested at the time of 852 
infection are shown as 0 h.p.i. in (c)-(e). In (a) no lysate was analyzed in lanes 2 853 
and 4. Proteins recognized by the antibodies used are indicated to the right of 854 
each figure. The positions of molecular mass markers (kDa) are indicated to the 855 
left of each figure. (b) Relative band intensity of CREB and CREB-Ser133 bands 856 
relative to E-actin signal in the same lane in Fig. 4(a), as quantified using ImageJ. 857 
Band intensities of 0-1, 1-2 and greater than 2 are highlighted in light grey, dark 858 
grey and black, respectively. 859 
 860 
Fig. 6 H3K14ac at the MIEP is unaffected in SB-734117 treated cells. DNA 861 
was immune-precipitated from infected cells (24-72hpi) treated with either DMSO 862 
or SB-734117 using an anti-H3K14ac antibody (K14) or isotype control (C), then 863 
amplified in an MIEP qPCR. Enrichment of MIEP sequences was expressed 864 
relative to amplification in Input sample. Data and error bars represent the mean 865 
and standard deviation of three PCR replicates from each sample, respectively  866 
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4-pyrimidinyl ortho-aryl azoles 31 0 31 
Oxindoles 30 3 27 
Furazan benzimidazoles 25 1 24 
4-anilino quinazolines and related 25 0 25 
Benzimidazole N-thiophenes 21 9 12 
4-pyridyl ortho-aryl azoles 18 0 18 
2H-3 pyrimidinyl pyrazolopyridazines 16 7 9 
2-amino oxazoles 15 0 15 
4-hydrazinly pyrazolopyrimidines 15 0 15 
2,4-dianilino pyrrolopyrimidines 15 1 14 
Biaryl amides 14 0 14 
3-vinyl pyridines 13 0 13 
Anilino thienopyrimidines 12 0 12 
Benzimidazolyl diaryl ureas 12 2 10 
2-aryl 3-pyridimidinyl pyrazolopyridazines 12 0 12 
2,4-diamino pyrimidines 12 0 12 
Maleimide 11 0 11 
Furopyrimidines and related 9 0 9 
Indazole-3-carboxamides 7 1 6 
3-amino pyrazolopyridines 7 3 4 
2-pyridinyl imidazoles and related 7 0 7 
4-anilino 5-alkynyl pyrimidines 7 0 7 
3-cyano thiophenes 6 2 4 
Phenyl carboxamides 6 0 6 
Indazole-5-carboxamides 6 0 6 
3-amino pyrazolopyridazines 4 1 3 
3-amino pyrazoles 3 0 3 
Imidazotriazine 3 0 3 
4-anilino quinolones 2 0 2 
6-phenyl isoquinolines 2 1 1 
3-benzyl pyrimidines 1 0 1 
 871 
 872 
 873 
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Table 2 874 
 875 
Experiment Viral Strain Compound ED50* (PM) 
1 AD169 SB-734117 0.5 
 AD169 GCV 0.5 
    
2 AD169 SB-734117 0.4 
 AD169-P53 SB-734117 1.3 
    
3 AD169 SB-734117 1 
 Merlin(RCMV1111) SB-734117 2 
*50% effective dose 876 
Ganciclovir 877 
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Compound treatment and infection of cells for high throughput screening. 
The GSK PKIS library [1] (stock concentration of 3.3 mM of each compound in 
DMSO) was screened in duplicate. Twenty four hours before infection 2000 HFF 
cells were seeded in each well of each Corning 384 plate. Unless stated 
otherwise, liquid was added to wells using a WellMate apparatus. At the time of 
infection, media was removed with a suction manifold and 30 µl of complete 
media was added to each well. Compounds were added to the plate containing 
HFF cells using a 100 nl pin transfer on a liquid handling robot. Negative and 
6XSSOHPHQWDU\0DWHULDO)LOHV &OLFNKHUHWRGRZQORDG6XSSOHPHQWDU\0DWHULDO)LOHV
EOV*6.6FUHHQ6833/(0(17$5<0$7(5,$/),1$/YSGI
positive controls (water+0.3% DMSO or heparin sulfate (5 µg/ml) + 0.3% DMSO, 
respectively) were added to plates by hand (12 wells of each). Cells were then 
infected with HCMV strain AD169 (MOI 1) in a total volume of 5 µl. Thus, the final 
concentration of compound in each well was 9.4 µM. Infected cells were 
incubated for 72 hours at 37oC, then prepared for analysis. 
 
Preparation of screening plates for high throughput microscopy analysis. 
Cell culture media was removed from infected cells and replaced with 20 µl 
Hoecsht 33342 (SIGMA) diluted in PBS to a final concentration of 10 µg/ml. After 
incubation for 1 hour at 37oC, 20 µl of Deep Red Cell Mask (Invitrogen) (diluted in 
PBS to a concentration of 5 µg/ml) was added to each well. Cells were incubated 
for a further 5 min at 37oC. Cells were then fixed by removing PBS containing 
Hoescht and Cell Mask and adding 50 µl of 3.5%Formaldyhyde (SIGMA) in PBS 
to each well. After incubating at room temperature for 10 min, fixative was 
removed and 50 µl of PBS containing 0.5% TritonX-100 was added per well to 
permeablize cells. After 10 min incubation at room temperature, PBS containing 
detergent was removed, and cells was washed once with PBS. PBS was 
removed and replaced with 20 µl MAb P207 recognizing pp28 (Virusys) (dilution 
1:1000) and anti-mouse secondary antibody conjugated to flurophore Alexa488 
(Molecular Probes) (dilution 1:1000). Plates were incubated at 37oC for 1 hour. 
After incubation, PBS containing antibodies was removed and replaced with 50 µl 
of PBS. Plates were then analyzed using automated microscopy for the presence 
of pp28 protein. 
 Microscopy analysis of screening plates. Infected cells stained with antibody 
to detect pp28 were imaged on an Image Express Micro (IXM) microscope 
(Molecular Devices) at 10x magnification to detect 3 wavelengths; 488 nm to 
detect antibody recognizing pp28, 568nm to detect Deep Red CellMask and 350 
nm to detect Hoescht 33342 stain bound to nuclear DNA. Three images were 
captured from each wavelength in each well of the 384-well plate. The number of 
cells positive at all 3 wavelengths and percentage of pp28 positive cells in each 
well was determined using the Metamorph Multiwavelength Cell Scoring software 
(Molecular Devices). Typically, approximately 60% of cells were infected in wells 
treated with negative control, DMSO (data not shown). 
 
Analysis of screening results. To assess the quality of data that could be 
returned from the screening protocol we calculated the Z’-factor [2, 3] derived 
from the positive (heparan sulphate treated infected cells) and negative (DMSO 
treated infected cells) control wells. The screening controls returned Z’-factors of 
greater than or equal to 0.5, indicating a robust separation of difference in the 
data derived from positive and negative controls (data not shown). Thus, the 
screening protocol could be reliably used to screen the compound collection. 
After screening of the compound collection, data was discarded from any 
well in which the number of cells stained with Hoescht 33342 fell below 2-fold of 
the mean of the number of cells in each well of the plate. The data from the 
remaining wells from each plate was converted to a z-score (the number of 
standard deviations from the mean of the data [2, 3]) and the average z-score 
from data in duplicate plates was determined. Images chosen at random were 
visually inspected throughout image capture and analysis to ensure raw data was 
consistent with z-scores. 
 
Characterization of compounds within the GSK PKIS collection. 
Characterization of compounds has been reported by Elkins and co-workers [4]. 
Kinase profiling was previously performed by using the Nanosyn microfluidics 
capillary electrophoresis technology (based on the change in electrophoretic 
mobility of a substrate upon phosphorylation) to determine each compounds 
ability to inhibit a panel of 224 recombinant kinase proteins. GPCR screening 
using calcium mobility assays was carried out as previously described [4]. The 
structure of each compound is available at ChEMBL 
(https://www.ebi.ac.uk/chembl/) [1]. 
 
Primary and secondary antibodies used in western blotting. Membranes 
were probed with antibodies recognizing IE1/2, UL44, pp28, UL84 (all Virusys, 
1:1000 dilution), IE2 proteins (clone 5A8.2, Millipore, 1:1000 dilution), !-actin 
(SIGMA, 1:5000 dilution), CREB (product no. 06-863) or CREB-Ser133 (product 
no. 06-519)  (both Millipore, 1:500 dilution). Antibody recognizing UL97 [5] was a 
kind gift from Donald Coen (Harvard Medical School, USA), respectively. All 
antibodies recognizing histone proteins were obtained from Cell Signaling 
Technology (products #9927, #9847, #9783) and used as per suppliers 
instructions. All primary antibodies were detected using anti-mouse- or anti-
rabbit-horseradish peroxidase (HRP) conjugated antibodies (Millipore and Cell 
Signaling Technology, respectively). Chemiluminescence solution (GE 
Healthcare) was used in each case to detect secondary antibodies using film. 
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